Publications

2022

Brady NJ, Barbieri CE. JAK inhibition shows two faces in prostate cancer. Nat Cancer. 2022;3(9):1021-1023.
Melanson SE, Zhao Z, Kumanovics A, Love T, Meng QH, Wu AH, et al. Tolerance for three commonly administered COVID-19 vaccines by healthcare professionals. Front Public Health. 2022;10:975781.
Melis M, Tang X-, Attarwala N, Chen Q, Prishker C, Qin L, et al. A retinoic acid receptor β2 agonist protects against alcohol liver disease and modulates hepatic expression of canonical retinoid metabolism genes. Biofactors. 2022;48(2):469-480.
Adhikari S, Guha D, Mohan C, Mukherjee S, Tyler JK, Das C. Reprogramming Carbohydrate Metabolism in Cancer and Its Role in Regulating the Tumor Microenvironment. Subcell Biochem. 2022;100:3-65.
Webster AL, Sanders MA, Patel K, Dietrich R, Noonan RJ, Lach FP, et al. Genomic signature of Fanconi anaemia DNA repair pathway deficiency in cancer. Nature. 2022;612(7940):495-502.
Haigh DB, Woodcock CL, Lothion-Roy J, Harris AE, Metzler VM, Persson JL, et al. The METTL3 RNA Methyltransferase Regulates Transcriptional Networks in Prostate Cancer. Cancers (Basel). 2022;14(20).
Weinberg OK, Siddon A, Madanat YF, Gagan J, Arber DA, Dal Cin P, et al. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv. 2022;6(9):2847-2853.
Cyrta J, Prandi D, Arora A, Hovelson DH, Sboner A, Rodriguez A, et al. Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies. J Pathol. 2022;257(3):274-284.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700